Rani Therapeutics Holdings (RANI) Accumulated Expenses (2020 - 2026)

Rani Therapeutics Holdings has reported Accumulated Expenses for 7 years, with the latest figure at $3.1 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 19.01% year-over-year to $3.1 million in Q2 2026; TTM through Jun 2026 was $3.1 million, a 19.01% increase from a year earlier, with the FY2025 full-year figure at $3.9 million, up 90.21% from the prior year.
• Accumulated Expenses was $3.1 million for Q2 2026 at Rani Therapeutics Holdings, down from $4.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $4.7 million in Q1 2026, with the low at $1.7 million in Q4 2023.
• Average Accumulated Expenses over 5 years is $2.9 million, with a median of $2.7 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Accumulated Expenses slumped 52.49% in 2024, then jumped 105.95% in 2026.
• Over 5 years, Accumulated Expenses stood at $2.3 million in 2022, then dropped by 26.52% to $1.7 million in 2023, then rose by 20.1% to $2.1 million in 2024, then surged by 90.21% to $3.9 million in 2025, then slipped by 20.44% to $3.1 million in 2026.
• The last three Accumulated Expenses figures came in at $3.1 million (Q2 2026), $4.7 million (Q1 2026), and $3.9 million (Q4 2025), per Business Quant data.